A challenge by...Novartis to India's patent law could have serious implications for future access to essential medicinces worldwide, aid agency Medecins Sans Frontieres said...Novartis says that it is concerned about India's failure to fully implement World Trade Organisation rules on intellectual property and that it could undermine growth of the country's life science industry, reducing access to life-saving drugs...The Swiss company also says generics are not the answer for the majority of patients in India, who still cannot afford them. More than 6,000 patients in India receive Novartis's Glivec free of charge, amounting to 99 percent of the drug in the country, the company says.